Detail akcie U.S. Stem Cell online

Business Summary: U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor - 1 or SDF-1 protein. The Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2022, US Stem Cell Inc revenues decreased 59% to $82K. Net loss decreased 13% to $2.9M. Revenues reflect Products decrease of 63% to $67K, Services decrease of 22% to $16K. Lower net loss reflects Marketing, general and administrative decrease of 22% to $1.8M (expense), Interest expense decrease of 31% to $690K (expense), Other Non Operating I/E decrease from $151K (expense) to $0K.